Barely Significant
← all excerpts

Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study.

Microb Biotechnol · 2025 · PMC12551668 · PMID 41134684

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant
Numerically higher remission and response rates were observed with first‐line UST compared to second‐line therapy, although the difference did not reach statistical significance ( p > 0.05). 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.